论文部分内容阅读
目的探讨贝尼地平、厄贝沙坦单独治疗和联合治疗对高血压病患者肾脏的影响。方法132例高血压病患者随机均分为3组:贝尼地平组(口服贝尼地平4 mg)、厄贝沙坦组(口服厄贝沙坦150 mg);联合治疗组(口服贝尼地平4 mg和厄贝沙坦150 mg)。疗程24周,治疗前后观察肾脏病常用实验室检查的变化。结果3组高血压病患者治疗后降低血压及尿蛋白排泄量(24 h尿白蛋白、24 h尿蛋白、血尿β2-微球蛋白)比较,差异有非常显著意义。联合治疗组降低尿蛋白排泄的幅度与贝尼地平组和厄贝沙坦组比较,差异有统计学意义,而贝尼地平组和厄贝沙坦组之间无统计学意义。治疗后肾小球滤过率在联合治疗组及厄贝沙坦组之间,差异有统计学意义,而贝尼地平组无明显变化。3组治疗后尿白蛋白下降幅度与血压下降程度均无显著相关性。结论贝尼地平、厄贝沙坦长期单独治疗均可减少蛋白尿,保护肾脏,两药联合治疗对减少蛋白尿,保护肾脏有一定协同作用。
Objective To investigate the effects of benidipine and irbesartan alone and combined therapy on the kidney of hypertensive patients. Methods 132 patients with essential hypertension were randomly divided into three groups: benidipine group (oral benidipine 4 mg), irbesartan group (oral irbesartan 150 mg); combination therapy group (oral benidipine 4 mg and irbesartan 150 mg). Treatment for 24 weeks, before and after treatment to observe changes in laboratory tests commonly used in kidney disease. Results The difference of blood pressure and urinary protein excretion (24 h urinary albumin, 24 h urinary protein and hematuria β2-microglobulin) in hypertensive patients after treatment was significantly different. Compared with benidipine group and irbesartan group, the difference of urinary protein excretion in combination therapy group was statistically significant, but there was no significant difference between benidipine group and irbesartan group. Glomerular filtration rate after treatment in the combination therapy group and irbesartan group, the difference was statistically significant, while the benidipine group had no significant change. There was no significant correlation between the decrease of urinary albumin and the decrease of blood pressure in the three groups after treatment. Conclusion Benidipine and irbesartan can both reduce proteinuria and protect the kidneys in the long term. The combination of the two drugs can reduce the proteinuria and protect the kidneys.